復旦微電(688385.SH)IPO認購結果:網上網下共棄購2.59萬股
格隆匯7月28日丨復旦微電(688385.SH)公佈,聯席主承銷商根據本次戰略投資者繳款情況,以及上交所和中國證券登記結算有限責任公司上海分公司提供的數據,對本次戰略配售、網上、網下發行的新股認購情況進行了統計。戰略配售情況如下:

網上、網下新股認購情況:
網上、網下投資者共棄購2.59萬股,將全部由主承銷商包銷,包銷金額約為16.16萬元,包銷股份數量佔扣除最終戰略配售部分後本次發行數量的比例為0.0309%,包銷股份數量佔本次發行總規模的比例為0.0216%。其中,網上投資者棄購2.26萬股,棄購金額約為14.09萬元;網下投資者棄購3326股,棄購金額為2.07萬元。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.